ImmuneeringIMRX
IMRX
About: Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Employees: 54
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
1.32% less ownership
Funds ownership: 13.86% [Q4 2024] → 12.53% (-1.32%) [Q1 2025]
17% less funds holding
Funds holding: 42 [Q4 2024] → 35 (-7) [Q1 2025]
27% less capital invested
Capital invested by funds: $9.32M [Q4 2024] → $6.84M (-$2.49M) [Q1 2025]
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
104%
upside
Avg. target
$13.25
200%
upside
High target
$21
375%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Graig Suvannavejh | 126%upside $10 | Outperform Maintained | 18 Jun 2025 |
Needham Ami Fadia | 104%upside $9 | Buy Reiterated | 18 Jun 2025 |
Chardan Capital Geulah Livshits | 194%upside $13 | Buy Maintained | 18 Jun 2025 |
Oppenheimer Jay Olson | 375%upside $21 | Outperform Maintained | 7 May 2025 |
Financial journalist opinion
Based on 3 articles about IMRX published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-lasting benefit by outpacing resistance mechanisms that cause cancer drugs to stop working - - Additional patent applications pending for atebimetinib directed to compounds, pharmaceutical compositions, and methods of use with expiration expected into 2044 - CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that the United States Patent and Trademark Office (USPTO) granted the company a composition of matter patent for atebimetinib (IMM-1-104), an oral once-daily deep cyclic inhibitor of MEK.
Neutral
GlobeNewsWire
3 weeks ago
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable - - Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile - - Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 - - Company to host conference call at 8:00 a.m. ET today - CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
3 weeks ago
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025.
Neutral
GlobeNewsWire
1 month ago
Immuneering to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company's pipeline, platform, and business strategy.
Neutral
GlobeNewsWire
2 months ago
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q'25 - - Reported positive data from the Company's ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer, and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer, to lead clinical efforts as the Company ramps up planning for Phase 3 trial in first line pancreatic cancer - - Cash runway extended into 2026 - CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the first quarter ended March 31, 2025, and provided several business updates.
Neutral
GlobeNewsWire
3 months ago
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company's pipeline, platform, and business strategy.
Neutral
GlobeNewsWire
3 months ago
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D.
Neutral
GlobeNewsWire
3 months ago
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for potential IMM-1-104 global pivotal trial - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer - - Cash runway extended into 2026 - CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates.
Neutral
GlobeNewsWire
3 months ago
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer.
Neutral
GlobeNewsWire
5 months ago
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company's pipeline, platform, and business strategy.
Charts implemented using Lightweight Charts™